Treatment-related adverse events of any grade in 5% or more in the overall population of 61 patients
| Adverse event | Decitabine-plus-camrelizumab (n=42) | Camrelizumab (n=19) | ||
| Any grade | Grade 3–4 | Any grade | Grade 3–4 | |
| Any adverse event | 41 (98) | 9 (21) | 19 (100) | 3 (16) |
| Reactive capillary endothelial proliferation | 36 (86) | 0 | 16 (84) | 0 |
| Leukocytopenia | 26 (62) | 9 (21) | 6 (32) | 0 |
| Fever | 16 (38) | 0 | 6 (32) | 2 (11) |
| Pain in the lesion | 8 (19) | 0 | 3 (16) | 0 |
| Increased triglyceride | 6 (14) | 0 | 2 (11) | 0 |
| Rash | 5 (12) | 0 | 0 (0) | 0 |
| Pneumonitis | 4 (10) | 1 (2) | 1 (5) | 1 (5) |
| Diarrhea | 4 (10) | 0 | 0 | 0 |
| Myalgia | 4 (10) | 0 | 0 (0) | 0 |
| Increased transaminase | 3 (7) | 0 | 3 (16) | 0 |
| Hypothyroidism | 3 (7) | 0 | 3 (16) | 0 |
| Increased UA | 3 (7) | 0 | 1 (5) | 0 |
| Myocardial ischemia | 3 (7) | 0 | 0 | 0 |
| Nausea | 3 (7) | 0 | 0 | 0 |
| Thrombocytosis | 2 (5) | 0 | 0 | 0 |
| Fatigue | 1 (2) | 0 | 2 (11) | 0 |
| Thrombocytopenia | 1 (2) | 0 | 1 (5) | 0 |
UA, Uric Acid.